MiR-25 Targets TNF-related Apoptosis Inducing Ligand (TRAIL) Death Receptor-4 and Promotes Apoptosis Resistance in Cholangiocarcinoma
Overview
Authors
Affiliations
Unlabelled: It has been established that microRNA expression and function contribute to phenotypic features of malignant cells, including resistance to apoptosis. Although targets and functional roles for a number of microRNAs have been described in cholangiocarcinoma, many additional microRNAs dysregulated in this tumor have not been assigned functional roles. In this study, we identify elevated miR-25 expression in malignant cholangiocarcinoma cell lines as well as patient samples. In cultured cells, treatment with the Smoothened inhibitor, cyclopamine, reduced miR-25 expression, suggesting Hedgehog signaling stimulates miR-25 production. Functionally, miR-25 was shown to protect cells against TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Correspondingly, antagonism of miR-25 in culture sensitized cells to apoptotic death. Computational analysis identified the TRAIL Death Receptor-4 (DR4) as a potential novel miR-25 target, and this prediction was confirmed by immunoblot, cell staining, and reporter assays.
Conclusion: These data implicate elevated miR-25 levels in the control of tumor cell apoptosis in cholangiocarcinoma. The identification of the novel miR-25 target DR4 provides a mechanism by which miR-25 contributes to evasion of TRAIL-induced cholangiocarcinoma apoptosis.
Gao H, Chen Z, Yao Y, He Y, Hu X Front Oncol. 2024; 14:1453090.
PMID: 39634266 PMC: 11614734. DOI: 10.3389/fonc.2024.1453090.
Bai M, Wang R, Huang C, Zhong R, Jiang N, Fu W Sci Rep. 2024; 14(1):29661.
PMID: 39613883 PMC: 11607416. DOI: 10.1038/s41598-024-81392-0.
Bestari M, Joewono I, Syam A Biomolecules. 2024; 14(3).
PMID: 38540782 PMC: 10968439. DOI: 10.3390/biom14030364.
Yang M, Li T, Guo S, Song K, Gong C, Huang N J Transl Med. 2024; 22(1):50.
PMID: 38216965 PMC: 10787510. DOI: 10.1186/s12967-023-04680-9.
Jin H, Liu W, Xu W, Zhou L, Luo H, Xu C Comput Math Methods Med. 2022; 2022:7102736.
PMID: 36158120 PMC: 9499749. DOI: 10.1155/2022/7102736.